139 related articles for article (PubMed ID: 29737104)
1. [Antibiotic Resistance and Risk Factors for Mortality of Blood Stream Infections (BSIs) with
Zhang WL; Huang J; Wu SY; Liu Y; Long F; Xiao YL; Xie Y; He C; Kang M
Sichuan Da Xue Xue Bao Yi Xue Ban; 2018 Jan; 49(1):133-135. PubMed ID: 29737104
[TBL] [Abstract][Full Text] [Related]
2. Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies.
Trecarichi EM; Tumbarello M; Spanu T; Caira M; Fianchi L; Chiusolo P; Fadda G; Leone G; Cauda R; Pagano L
J Infect; 2009 Apr; 58(4):299-307. PubMed ID: 19272650
[TBL] [Abstract][Full Text] [Related]
3. Clinical characteristics and outcome of critically ill patients with bacteremia caused by extended-spectrum β-lactamase-producing and non-producing Escherichia coli.
Haruki Y; Hagiya H; Haruki M; Sugiyama T
J Infect Chemother; 2018 Nov; 24(11):944-947. PubMed ID: 29803763
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for infection and treatment outcome of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in patients with hematologic malignancy.
Kang CI; Chung DR; Ko KS; Peck KR; Song JH;
Ann Hematol; 2012 Jan; 91(1):115-21. PubMed ID: 21556875
[TBL] [Abstract][Full Text] [Related]
5. Risk factors and outcomes in non-transplant patients with extended-spectrum beta-lactamase-producing
Xiao T; Yang K; Zhou Y; Zhang S; Ji J; Ying C; Shen P; Xiao Y
Antimicrob Resist Infect Control; 2019; 8():144. PubMed ID: 31467670
[TBL] [Abstract][Full Text] [Related]
6. ESBL-producing Escherichia coli isolated from bloodstream infections--antimicrobial susceptibility, conjugative transfer of resistance genes and phylogenetic origin.
Franiczek R; Krzyżanowska B
Adv Clin Exp Med; 2014; 23(6):865-70. PubMed ID: 25618110
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of risk factors for the acquisition of bloodstream infections with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in the intensive care unit; antibiotic management and clinical outcome.
Cordery RJ; Roberts CH; Cooper SJ; Bellinghan G; Shetty N
J Hosp Infect; 2008 Feb; 68(2):108-15. PubMed ID: 18063198
[TBL] [Abstract][Full Text] [Related]
8. Outcomes and risk factors for mortality in community-onset bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli, with a special emphasis on antimicrobial therapy.
Kang CI; Wi YM; Ko KS; Chung DR; Peck KR; Lee NY; Song JH
Scand J Infect Dis; 2013 Jul; 45(7):519-25. PubMed ID: 23509913
[TBL] [Abstract][Full Text] [Related]
9. Molecular analysis and risk factors for Escherichia coli producing extended-spectrum β-lactamase bloodstream infection in hematological malignancies.
Cornejo-Juárez P; Pérez-Jiménez C; Silva-Sánchez J; Velázquez-Acosta C; González-Lara F; Reyna-Flores F; Sánchez-Pérez A; Volkow-Fernández P
PLoS One; 2012; 7(4):e35780. PubMed ID: 22540004
[TBL] [Abstract][Full Text] [Related]
10. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy.
Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
Antimicrob Agents Chemother; 2004 Dec; 48(12):4574-81. PubMed ID: 15561828
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for, and clinical relevance of, faecal extended-spectrum β-lactamase producing Escherichia coli (ESBL-EC) carriage in neutropenic patients with haematological malignancies.
Arnan M; Gudiol C; Calatayud L; Liñares J; Dominguez MÁ; Batlle M; Ribera JM; Carratalà J; Gudiol F
Eur J Clin Microbiol Infect Dis; 2011 Mar; 30(3):355-60. PubMed ID: 21052757
[TBL] [Abstract][Full Text] [Related]
12. Fecal ESBL Escherichia coli carriage as a risk factor for bacteremia in patients with hematological malignancies.
Cornejo-Juárez P; Suárez-Cuenca JA; Volkow-Fernández P; Silva-Sánchez J; Barrios-Camacho H; Nájera-León E; Velázquez-Acosta C; Vilar-Compte D
Support Care Cancer; 2016 Jan; 24(1):253-259. PubMed ID: 26014616
[TBL] [Abstract][Full Text] [Related]
13. Clinical Characteristics of Bacteremia Caused by Extended-spectrum Beta-lactamase-producing Escherichia coli at a Tertiary Hospital.
Namikawa H; Yamada K; Fujimoto H; Oinuma KI; Tochino Y; Takemoto Y; Kaneko Y; Shuto T; Kakeya H
Intern Med; 2017; 56(14):1807-1815. PubMed ID: 28717075
[TBL] [Abstract][Full Text] [Related]
14. Risk factors, outcome and impact of empirical antimicrobial treatment in extended-spectrum β-lactamase-producing Escherichia coli bacteraemia.
Van Aken S; Lund N; Ahl J; Odenholt I; Tham J
Scand J Infect Dis; 2014 Nov; 46(11):753-62. PubMed ID: 25195648
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial resistance patterns, clinical features, and risk factors for septic shock and death of nosocomial E coli bacteremia in adult patients with hematological disease: A monocenter retrospective study in China.
Ma J; Li N; Liu Y; Wang C; Liu X; Chen S; Xie X; Gan S; Wang M; Cao W; Wang F; Liu Y; Wan D; Sun L; Sun H
Medicine (Baltimore); 2017 May; 96(21):e6959. PubMed ID: 28538389
[TBL] [Abstract][Full Text] [Related]
16. Prevalence, risk factors, and impact on clinical outcome of extended-spectrum beta-lactamase-producing Escherichia coli bacteraemia: a five-year study.
Denis B; Lafaurie M; Donay JL; Fontaine JP; Oksenhendler E; Raffoux E; Hennequin C; Allez M; Socie G; Maziers N; Porcher R; Molina JM
Int J Infect Dis; 2015 Oct; 39():1-6. PubMed ID: 26189774
[TBL] [Abstract][Full Text] [Related]
17. Mortality and length of hospital stay after bloodstream infections caused by ESBL-producing compared to non-ESBL-producing
Handal N; Whitworth J; Lyngbakken MN; Berdal JE; Dalgard O; Bakken Jørgensen S
Infect Dis (Lond); 2024 Jan; 56(1):19-31. PubMed ID: 37795955
[TBL] [Abstract][Full Text] [Related]
18. Epidemiology and clinical outcomes of bloodstream infections caused by extended-spectrum β-lactamase-producing Escherichia coli in patients with cancer.
Ha YE; Kang CI; Cha MK; Park SY; Wi YM; Chung DR; Peck KR; Lee NY; Song JH
Int J Antimicrob Agents; 2013 Nov; 42(5):403-9. PubMed ID: 24071027
[TBL] [Abstract][Full Text] [Related]
19. Nosocomial bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae resistant to third-generation cephalosporins, Finland, 1999-2013: Trends, patient characteristics and mortality.
Martelius T; Jalava J; Kärki T; Möttönen T; Ollgren J; Lyytikäinen O;
Infect Dis (Lond); 2016; 48(3):229-34. PubMed ID: 26577519
[TBL] [Abstract][Full Text] [Related]
20. Bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome.
Gudiol C; Calatayud L; Garcia-Vidal C; Lora-Tamayo J; Cisnal M; Duarte R; Arnan M; Marin M; Carratalà J; Gudiol F
J Antimicrob Chemother; 2010 Feb; 65(2):333-41. PubMed ID: 19959544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
